A phase ii clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors

55Citations
Citations of this article
61Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: The liver is the predominant site of metastases among patients with advanced neuroendocrine tumors (NETs). Prior retrospective studies have reported high response rates in patients treated with transarterial embolization (TAE). NETs are highly vascular and are known to express vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR). We hypothesized that administration of sunitinib, a VEGFR inhibitor, following TAE would extend progression-free survival (PFS). Patients and methods: Patients with metastatic NETs to the liver underwent a series of selective TAEs followed by sunitinib (until disease progression or maximum of 12 months). Radiographic response (by RECIST), survival, and safety parameters were monitored. Results: Thirty-nine patients were enrolled. The overall response rate was 72% [95% confidence interval (CI),0.58-0.86]. Median PFS was 15.2 months. Rates of overall survival (OS) at 1 and 4 years were 95% (95% CI, 0.88-1.00) and 59% (95% CI, 0.38-0.80), respectively. A significant 34% rise in serum VEGF was observed following the initial TAE (P = 0.03). Conclusions: Hepatic TAE is a highly active treatment option for patients with metastatic NETs to the liver. Embolization stimulates release of VEGF into the circulation. Sunitinib, an oral VEGFR inhibitor, can be safely administered following embolization. The high rates of PFS and OS associated with this sequence of therapies are encouraging. © The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Author supplied keywords

References Powered by Scopus

Everolimus for advanced pancreatic neuroendocrine tumors

2514Citations
N/AReaders
Get full text

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

2203Citations
N/AReaders
Get full text

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group

2135Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Neuroendocrine tumors, version 1.2015

307Citations
N/AReaders
Get full text

Neuroendocrine and adrenal tumors, version 2.2018 featured updates to the nccn guidelines

299Citations
N/AReaders
Get full text

Angiogenesis as a hallmark of solid tumors - clinical perspectives

171Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Strosberg, J. R., Weber, J. M., Choi, J., Campos, T. L., Valone, T. L., Han, G., … Kvols, L. K. (2012). A phase ii clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Annals of Oncology, 23(9), 2335–2341. https://doi.org/10.1093/annonc/mdr614

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 19

53%

Researcher 9

25%

Professor / Associate Prof. 8

22%

Readers' Discipline

Tooltip

Medicine and Dentistry 31

79%

Nursing and Health Professions 4

10%

Neuroscience 2

5%

Psychology 2

5%

Save time finding and organizing research with Mendeley

Sign up for free